Literature DB >> 24957187

Newer antiepileptic drugs: evidence based use.

Gouri Rao Passi1.   

Abstract

Several new antiepileptic drugs (AED's) have been approved by the FDA in the last 2 decades. The newer AED's score over the older ones, in terms of improved tolerability, safety, improved pharmacokinetics and lower drug-drug interactions. However, efficacy may not be significantly higher. This article reviews the newer antiepileptics approved in the pediatric age group and the evidence for or against their clinical use.

Mesh：

Substances：

Year:  2014        PMID： 24957187     DOI： 10.1007/s12098-014-1494-4

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


  48 in total

1.  A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group.

Authors:  R D Elterman; T A Glauser; E Wyllie; R Reife; S C Wu; G Pledger
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

Review 2.  Antiepileptic drugs 2012: recent advances and trends.

Authors:  Joseph I Sirven; Katherine Noe; Matthew Hoerth; Joseph Drazkowski
Journal:  Mayo Clin Proc       Date:  2012-09       Impact factor: 7.616

Review 3.  Levetiracetam in pediatrics.

Authors:  Federico Vigevano
Journal:  J Child Neurol       Date:  2005-02       Impact factor: 1.987

4.  Visual field defects associated with vigabatrin therapy.

Authors:  M C Lawden; T Eke; C Degg; G F Harding; J M Wild
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

5.  Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience.

Authors:  K Mohamed; R Appleton; L Rosenbloom
Journal:  Seizure       Date:  2000-03       Impact factor: 3.184

6.  Randomized trial of vigabatrin in patients with infantile spasms.

Authors:  R D Elterman; W D Shields; K A Mansfield; J Nakagawa
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

7.  Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy.

Authors:  Ahmad Beydoun; Rajesh C Sachdeo; Ekrem Kutluay; Kevin McCague; Joseph D'Souza
Journal:  Epilepsia       Date:  2003-09       Impact factor: 5.864

8.  Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review.

Authors:  Hui Jeen Tan; Timothy R Martland; Richard E Appleton; Rachel Kneen
Journal:  Seizure       Date:  2009-11-25       Impact factor: 3.184

9.  Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study).

Authors:  Ingo Borggraefe; Michaela Bonfert; Thomas Bast; Bernd Axel Neubauer; Klaus Juergen Schotten; Kai Maßmann; Soheyl Noachtar; Ingrid Tuxhorn; Theodor W May; Florian Heinen
Journal:  Eur J Paediatr Neurol       Date:  2013-04-30       Impact factor: 3.140

10.  Safety and efficacy of vigabatrin for the treatment of infantile spasms.

Authors:  Michele A Faulkner; Justin A Tolman
Journal:  J Cent Nerv Syst Dis       Date:  2011-09-14
View more
  2 in total

1.  Editorial.

Authors:  Pratibha Singhi
Journal:  Indian J Pediatr       Date:  2014-08-08       Impact factor: 1.967

2.  Antiepileptic drug use in Italian children over a decade.

Authors:  Daria Putignano; Antonio Clavenna; Rita Campi; Angela Bortolotti; Ida Fortino; Luca Merlino; Aglaia Vignoli; Maria Paola Canevini; Maurizio Bonati
Journal:  Eur J Clin Pharmacol       Date:  2016-11-26       Impact factor: 2.953
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.